Ad
related to: should i sell merck stock current
Search results
Results from the WOW.Com Content Network
There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates ...
Merck's current forward price-to-earnings ratio stands at 14.5, well below the big pharma peer group average of 17. This valuation suggests that despite the recent stock surge, Merck may still be ...
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...
Keytruda has been the best-selling medicine in the world since last year, when it generated $25 billion in sales. Merck's total revenue for the year was $60.1 billion, so Keytruda accounted for ...
Before you buy stock in Merck, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one ...
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Ad
related to: should i sell merck stock current